RT Journal Article
T1 Liquid Biopsy Biomarkers in Bladder Cancer: A Current Need for Patient Diagnosis and Monitoring.
A1 Lodewijk, Iris
A1 Dueñas, Marta
A1 Rubio, Carolina
A1 Munera-Maravilla, Ester
A1 Segovia, Cristina
A1 Bernardini, Alejandra
A1 Teijeira, Alicia
A1 Paramio, Jesús M
A1 Suárez-Cabrera, Cristian
K1 biomarkers
K1 bladder cancer
K1 liquid biopsy
AB Bladder Cancer (BC) represents a clinical and social challenge due to its high incidence and recurrence rates, as well as the limited advances in effective disease management. Currently, a combination of cytology and cystoscopy is the routinely used methodology for diagnosis, prognosis and disease surveillance. However, both the poor sensitivity of cytology tests as well as the high invasiveness and big variation in tumour stage and grade interpretation using cystoscopy, emphasizes the urgent need for improvements in BC clinical guidance. Liquid biopsy represents a new non-invasive approach that has been extensively studied over the last decade and holds great promise. Even though its clinical use is still compromised, multiple studies have recently focused on the potential application of biomarkers in liquid biopsies for BC, including circulating tumour cells and DNA, RNAs, proteins and peptides, metabolites and extracellular vesicles. In this review, we summarize the present knowledge on the different types of biomarkers, their potential use in liquid biopsy and clinical applications in BC.
YR 2018
FD 2018-08-24
LK https://hdl.handle.net/10668/25470
UL https://hdl.handle.net/10668/25470
LA en
DS RISalud
RD Apr 17, 2025